Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Three SOLV Energy PV and BESS Sites Receive Top-Level Safety Recognition


Of 16 total participants in the state, SOLV Energy’s three jobsites are the only solar electric power generation projects to earn the recognition.

Three SOLV Energy projects in California were recognized as workplace safety and health leaders through the California Voluntary Protection Program (Cal/VPP) for non-fixed construction sites. Cal/VPP is Cal/OSHA’s top-level safety and leadership program recognizing employers who have voluntarily managed outstanding safety and health programs.

The VPP-Construction participants are Victory Pass PV & BESS, Arica PV & BESS and Oberon 1-2 PV & BESS, all located in Desert Center, CA. Of 16 total participants in the state, SOLV Energy’s three jobsites are the only solar electric power generation projects to earn the recognition.

Cal/VPP Construction participants are evaluated on management commitment to and employee involvement in the company’s health and safety programs. Among worksites in the same industry, Cal/VPP Construction worksites are expected to have significantly lower risks for accidents and injuries. SOLV Energy is the only solar Engineering, Procurement and Construction (EPC) contractor on the VPP-Construction Participant list.

A highlight of SOLV Energy’s safety system is the Near-Miss Program. Using the company’s proprietary project management app, Sunscreen, workers on jobsites can record near-misses in real-time on a tablet or mobile device. This company-wide platform increases transparency, encourages active participation and strengthens teamwork throughout the organization, keeping safety top-of-mind when working.

“Safety is at the foundation of everything we do. Providing safe workplaces and fostering a culture rooted in our core values puts our people first. This is an effort we all participate in, and the programs, tools and training our safety team designed for SOLV Energy empowers everyone to do their part to keep their teams safe,” said George Hershman, CEO of SOLV Energy.

Cal/OSHA will recognize the Arica, Oberon and Victory Pass sites as Cal/VPP Construction partners at a flag-raising ceremony on July 11th in Desert Center, CA.

Share article on social media or email:

Parkinson’s Disease Patients Gain Knowledge, Tools & Plans at One-of-a-Kind Summer School Designed to Improve Quality of Life.


People living with Parkinson's disease are encouraged to incorporate movement, exercise, and nutrition as part of a comprehensive, personlaized plan for health and well-being.

Parkinson’s Disease Summer School equips people living with Parkinson’s disease, and their partners, with evidence-based, real-world actions they can use to enhance quality of life.

Parkinson’s Disease Summer School participants and their partners go home with biologically plausible, real-world actions they can use.

Parkinson’s Disease (PD) Summer School starts Monday, July 31 through August 4 at Bastyr University in Kenmore; turn-out is expected to be the highest on record. This year the team will host a unique PD School Alumni Intensive weekend from Friday August 4 – August 6.

People living with Parkinson’s disease and their partners flock to the Northwest to learn how to reduce symptoms, regain function, and gather experiential guidance from some of the nation’s leading Parkinson’s disease experts at PD Summer School.

Laurie Mischley, ND, MPH, Ph.D., an acclaimed clinical researcher specializing in the study of Parkinson’s disease, leads PD Summer School. She started the program because Parkinson’s patients want to know what role they can play in everyday life to delay symptoms and live vibrantly.

“Parkinson’s Disease Summer School participants and their partners go home with biologically plausible, real-world actions they can use,” says Dr. Mischley. “The therapies we teach are evidence-based and supported by published peer-reviewed literature.”

All attendees get the latest information on medications, environmental toxins, rest and recovery, nutrition and diet, movement, exercise and more from some of the world’s top Parkinson’s disease experts. The roster of care providers includes:

  • Naturopathic doctors
  • Neurologists who focus on movement disorders
  • Physical therapists from the Parkinson’s Fitness Project
  • Yoga with a Parkinson’s Wellness Recovery (PWR) certified instructor
  • Counseling and mental health therapy for treatment-resistant conditions

First-time participants pay $3,750 for PD Summer Camp; partners pay $1,750. Included are:

  • Recommendations designed for participants’ unique symptoms, situations, and priorities.
  • Nutritionist-designed, chef-prepared meals
  • The newest evidence-based information about nutrition and diet, medications, environmental toxins, exercise, and more to support empowered decision-making and lifestyle choices
  • Therapeutic care including guided meditation, movement, and exercise classes

About Bastyr University

Bastyr University is a nonprofit, private university offering doctoral, graduate, and undergraduate degrees, with a multidisciplinary curriculum in science-based natural health and medicine. Recognized globally for its rigorous curriculum and strong research, Bastyr University has campuses in Kenmore, Washington, and San Diego, California. Bastyr’s international faculty educate future leaders in the natural health arts and sciences, with an emphasis on integrating mind, body, spirit, and nature. Parkinson’s Disease (PD) Summer School starts Monday, July 31 through August 4 at Bastyr University in Kenmore; turn-out is expected to be the highest on record. This year the team will host a unique PD School Alumni Intensive weekend from Friday August 4 – August 6.

People living with Parkinson’s disease and their partners flock to the Northwest to learn how to reduce symptoms, regain function, and gather experiential guidance from some of the nation’s leading Parkinson’s disease experts at PD Summer School.

Laurie Mischley, ND, MPH, Ph.D., an acclaimed clinical researcher specializing in the study of Parkinson’s disease, leads PD Summer School. She started the program because Parkinson’s patients want to know what role they can play in everyday life to delay symptoms and live vibrantly.

“Parkinson’s Disease Summer School participants and their partners go home with biologically plausible, real-world actions they can use,” says Dr. Mischley. “The therapies we teach are evidence-based and supported by published peer-reviewed literature.”

All attendees get the latest information on medications, environmental toxins, rest and recovery, nutrition and diet, movement, exercise and more from some of the world’s top Parkinson’s disease experts. The roster of care providers includes:

  • Naturopathic doctors
  • Neurologists who focus on movement disorders
  • Physical therapists from the Parkinson’s Fitness Project
  • Yoga with a Parkinson’s Wellness Recovery (PWR) certified instructor
  • Counseling and mental health therapy for treatment-resistant conditions

First-time participants pay $3,750 for PD Summer Camp; partners pay $1,750. Included are:

  • Recommendations designed for participants’ unique symptoms, situations, and priorities.
  • Nutritionist-designed, chef-prepared meals
  • The newest evidence-based information about nutrition and diet, medications, environmental toxins, exercise, and more to support empowered decision-making and lifestyle choices
  • Therapeutic care including guided meditation, movement, and exercise classes

About Bastyr University

Bastyr University is a nonprofit, private university offering doctoral, graduate, and undergraduate degrees, with a multidisciplinary curriculum in science-based natural health and medicine. Recognized globally for its rigorous curriculum and strong research, Bastyr University has campuses in Kenmore, Washington, and San Diego, California. Bastyr’s international faculty educate future leaders in the natural health arts and sciences, with an emphasis on integrating mind, body, spirit, and nature. For more information, please visit http://www.bastyr.edu.

Share article on social media or email:

Northeast Delta HSA to host Opioid Summit on June 15, “Building Resilience for Recovery through Trauma-Informed Care”


Northeast Delta HSA to host Opioid Summit on June 15,

Northeast Delta HSA to host Opioid Summit on June 15,

“With our Opioid Summit, we intend to inform, inspire, equip, and empower those who attend so that the regional safety net we are building can become even stronger and better able to serve those with complex addiction, mental illness, and primary healthcare needs.”

Northeast Delta Human Services Authority (NEDHSA) is set to host its 2023 Opioid Summit on Thursday, June 15, from 9 a.m. to 4 p.m. at the Bayou Pointe Event Center at the University of Louisiana Monroe. The theme for the 2023 Opioid Summit is “Building Resilience for Recovery through Trauma-Informed Care.”

NEDHSA Executive Director Dr. Monteic A. Sizer said, “we are seeing a resurgence of opioid-related treatment needs, arrests, hospitalizations, and deaths in our region, state, and across the nation. This event will help inspire others to learn how to work more collaboratively as we seek to resolve this complex issue collectively.”

“Our current opioid crisis will be mitigated when we learn how to effectively work across race, class, governmental silos, and political divisions. Additionally, opioid addiction will be mitigated once we develop enough compassion for those addicted and get them the evidence-based treatment they need, work to reduce those negative social determinants that drive their addiction, and help the people addicted to opioids find something to live for other than drugs,” Dr. Sizer said. “With our Opioid Summit, we intend to inform, inspire, equip, and empower those who attend so that the regional safety net we are building can become even stronger and better able to serve those with complex addiction, mental illness, and primary healthcare needs.”

NEDHSA’s Opioid Summit is an opportunity for behavioral health professionals, primary healthcare workers, law enforcement, federal, state, and local officials, clergy, and advocates to come together and collaborate on how to meet this complex societal issue with action. NARCAN training and distribution will also be available to all attendees.

Diana Kelly, Licensed Clinical Social Worker (LCSW), Master Clinical Consultant for the Consulting and Training Team at the Hazelden Betty Ford Foundation, will be this event’s keynote speaker.

Kelly is an LCSW, Clinician, Army Veteran, educator, and Master Clinical Consultant at the Hazelden Betty Ford Foundation and serves as an adjunct faculty member at the Indiana University School of Social Work in Indianapolis, Indiana. As a person in long-term recovery and a clinician working in substance use disorder recovery for over 13 years, Kelly has a deep personal passion for working with those impacted by trauma and substance use disorders, especially those impacted by the opioid crisis.

Other panelists and speakers include Dr. Sizer; Darryl Cowan, Drug Enforcement Agency (DEA) Agency; Dr. Avius Carroll, Director of NEDHSA’s Prevention & Wellness Department; along with a panel discussion, comprised of professionals and peers currently working with individuals affected by OUD/SUD.

To register for this event as a participant and/or vendor, visit: nedhsaopioid2023.eventbrite.com

For more information, contact Kara Etienne at kara.etienne@la.gov.

Share article on social media or email:

iCleanse Adds 30+ New Pilot Programs Including New England’s Second Largest Airport to Its Growing National Customer List


iCleanse is the leading device disinfection and Digital Out of Home (DOOH) media company.

“We’re thrilled to add more than 30 pilot programs to our customer list as we continue to grow our digital OOH network into more high traffic venues,” said iCleanse CEO Chris Allen.

iCleanse, the leading device disinfection and Digital Out of Home (DOOH) media company, announced today its first-of-its-kind disinfection product, Swift UV, has been installed in pilot programs at more than 30 locations nationwide.

Many of the new locations are in the hospitality industry and include: CT Science Center in Hartford, CT; Hartford Health Care Pain Treatment Center in West Hartford, CT; Swiches Coffee & Donuts in Berlin, CT; Kinsman Brewing Co. in Milldale, CT; Vagabond Inn in San Luis Obispo, CA; Ocean Palms Motel in Pismo Beach, CA; Harbor House Inn in Morro Bay, CA; Gateway Lodge in Seaside, CA; Beachwalker Inn in Pismo Beach, CA; ARI in Glastonbury, CT; Garde Art Center in New London, CT; Phenix Salon (464 & 465) in Woodbridge, NJ; Phenix Salon (1235) in Union, NJ; Sandwich Lodge & Resort in Sandwich, MA; Best Western – Bridgewood Hotel in Neenah, WI; Elmwood Barbershop in West Hartford, CT; American Distilling in East Hampton, CT; Holiday Inn Long Island Slip Airport in Holtsville, NY; Rancho Bernardo Inn in San Diego, CA; Candlewood Suites in Olive Branch, MS; Best Western Plus in Crawfordsville, IN; Econolodge in West Memphis, AR; Mircotel Inn & Suites by Wyndham in Tuscaloosa, AL; Motel 8 in Tuscaloosa, AL; SureStay Plus by Best Western in Smithfield, RI; Atlantic Motelin East Wareham, MA; Days Inn & Suites by Wyndham in Castle Rock, CO; Best Western Aurora in Aurora, CO; Aaspire NY Inc. in New York, NY; Motel 8 in Knoxville, TN.

Bradley International Airport in Connecticut, New England’s second largest airport, recently deployed four Swift UV devices from iCleanse joining more than 100 hospitals, organizations and retail locations nationwide that presently use the company’s patented and touchless UV disinfection that kills 99.99% of pathogens. To date, more than 1 million phones have been disinfected and 1 million impressions delivered using iCleanse’s Swift UV units.

“We’re thrilled to add more than 30 pilot programs to our customer list as we continue to grow our digital OOH network into more high traffic venues,” said iCleanse CEO Chris Allen. “Dozens of hospitals, organizations and retail locations already utilize our Swift UV product. We’ll continue to expand our footprint into airports, hotels, restaurants and other high traffic travel areas. This is a fantastic no-charge service that travelers appreciate. It also offers advertisers a unique one-to-one interaction with travelers and their brand. We look forward to deploying iCleanse in more locations nationwide this year.”

Swift UV is the most innovative new way for brands to directly engage one-on-one with their customers. Ad content can be fully customized and deployed across a fleet of units through the secure iCleanse Cloud. Companies can create their own design, or iCleanse will create custom content for the advertisers, that delivers an impactful interactive call-to-action for the Swift UV user. Brands can easily target and reach their desired consumer with coupon discount codes. Companies using iCleanse as an advertising and communication tool find they build sustainable brand loyalty and also expand their customer base.

Visit https://icleanse.com/ to learn more about iCleanse.

About iCleanse

In 2020, entrepreneur Chris Allen acquired ReadyDock, an established force in the UV-C hospital disinfection space since 2015. Allen re-branded the company as iCleanse and quickly transformed it into the leading device disinfection and Digital Out of Home (DOOH) media company it is today. iCleanse’s specialty is fast and chemical-free UV-C disinfection for mobile phones in high-traffic areas. The company’s first-of-its-kind product, Swift UV, features a display screen and advertising platform that allows the business owner to offer mobile phone disinfection while simultaneously monetizing traffic. More than 100 hospitals, organizations and retail locations nationwide use iCleanse for its fast and patented solution, while trusting its reliable and touchless UV disinfection.

Media Contact:

Chelsey Clapper, VP Marketing & Design

chelseyclapper@icleanse.com

Share article on social media or email:

ClinOne and Mural Health Partner to Maximize Patient Experience While Minimizing Site Burden


News Image

We are thrilled to be working with ClinOne, Andrea and her team share our values and mission. By embedding Mural Link into the ClinOne tech family, we will be able to further streamline site-level operations and empower ClinOne to improve the participant journey for studies its supports.

ClinOne, the leading provider of adaptive clinical trial experience solutions, has today announced a strategic partnership with Mural Health, a clinical trials technology company that improves the patient and caregiver experience in clinical trials. The move will integrate Mural Link, a next generation patient payments and participant management platform, into ClinOne’s patient support and trial management technology. The partnership will further streamline site-level operations and improve the participant journey.

Both companies are using technology to help sponsors overcome the stubborn challenges of drug development, including poor recruitment and retention, by focusing product design on the participant (the end-user). Both companies are also committed to reducing the administrative burden that clinical research sites can experience when sponsors require multiple technology platforms.

Mural Link is an innovative platform that optimizes the participant experience, strategically leveraging next-gen clinical trial payment technology, to continually engage patients and caregivers. Mural Link’s novel strategy and market leading technology platform eliminates financial barriers to enrollment, improves site-level operations, and, ultimately, speeds trial execution while improving the quality of the clinical data set. ClinOne shares the same mission, providing a selection of patient engagement solutions, including consent management, medication adherence monitoring, clinic visit ride hailing, a patient and caregiver portal, and e-diaries, in a single platform.

The partnership, announced today, embeds Mural Link into ClinOne’s suite of solutions, creating a seamless user experience for patients and sites alike.

“Mural Health offers a truly innovative approach to improving clinical trials,” Andrea Valente, CEO at ClinOne, said. “Making participation easy and focusing on efficient study operations align with our goals. We are very excited to partner with the Mural Health team to bring a superior experience to all participants during their clinical trial journey.”

Mural Health’s Co-Founder and Co-CEO, Sam Whitaker said: “We are thrilled to be working with ClinOne, Andrea and her team share our values and mission. By embedding Mural Link into the ClinOne tech family, we will be able to further streamline site-level operations and empower ClinOne to improve the participant journey for studies its supports.”

About Mural Health

Mural Health is a next-generation participant management platform. The Company’s Mural Link technology platform is designed to make it easier to participate in clinical trials, thereby improving study operation and the quality of clinical data sets. Mural Link offers next-generation participant payment technology that gives participants the power to choose how they receive payment, eliminates predatory fees related to prepaid debit cards, introduces functionality to help patients arrive at site visits (without incurring a cash expense), empowers communication between participants and site personnel, and captures participant data to predict individuals who are likely to drop-out. The Mural Link platform can be easily deployed to positively improve participant retention and engagement, increase protocol compliance, and increase enrollment rates. Please reach out to us to learn more about or capabilities, http://www.muralhealth.com or general@muralhealth.com.

About ClinOne

ClinOne connects, informs and empowers patients, caregivers and sites in clinical trials with a true single platform for trial awareness, consent management and patient engagement underpinned with comprehensive data insights tools. Used by more than 80 sponsors, CROs and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly and CNS. Designed in collaboration with sites and with participants and caregivers in mind, ClinOne features the industry’s fastest deployment, cost-efficient scale for trials of all sizes and seamless API integrations to provide the results you need and the experience your patients deserve. Ready to keep patients, sites and study teams active and engaged throughout your clinical trial? Let’s get creative at http://www.clinone.com.

Share article on social media or email:

Medical Weight Loss Clinic Enhances Prescribed Medications for Patients


News Image

“Our goal is to continue to provide personalized weight loss solutions for each of our patients,” said Medical Weight Loss Clinic Medical Director, Dr. David Rabens. “We believe that enhancing our prescription medication programs will better help our patients while achieving that goal.”

Medical Weight Loss Clinic(MWLC), a leading provider of physician-supervised weight loss programs in Michigan and Ohio, announced that they are enhancing its prescription medication offerings as part of their comprehensive weight loss programs.

MWLC now offers weight loss medications, such as semaglutide and tirzepatide, at lower prices with no fulfillment issues due to a recent partnership with Nationally-Certified Compounding Pharmacy, ACA Pharmacy, based in Nashville. These medications will be prescribed on a case-by-case basis and will be closely monitored by the clinic’s medical professionals.

The medications now being offered comes after careful consideration and consultation with its medical staff. MWLC believes that prescription medication, when used in conjunction with a healthy diet and exercise, can be a useful tool in helping individuals achieve their weight loss goals.

“We are thrilled to be improving our prescription medication program for our patients,” said MWLC Medical Director, Dr. David Rabens. “Prescription medication can be especially beneficial for patients who have struggled to lose weight through traditional diet and exercise methods.”

In addition to prescription medication, MWLC offers a variety of weight loss programs tailored to meet the needs of each individual patient. These programs include meal planning, exercise guidance, and behavior modification techniques.

“Our goal is to continue to provide personalized weight loss solutions for each of our patients,” said Rabens. “We believe that enhancing our prescription medication programs will better help our patients while achieving that goal.”

For more information about MWLC’s weight loss programs or to schedule a consultation, please visit https://mwlc.com/prescriptions.

ABOUT MEDICAL WEIGHT LOSS CLINIC

Founded in 1986, Medical Weight Loss Clinic is a Southfield Mich.-based company celebrating 37 years of professional, clinical weight loss experience. The experienced team at Medical Weight Loss Clinic has helped tens of thousands of people gain control of their weight, and their lives, through individually customized, non-surgical weight loss programs. The Southfield-based company operates 30 locations across Michigan and Ohio. Learn more at http://www.mwlc.com or connect on Facebook and YouTube.

Share article on social media or email:

AI Outperformed Standard Risk Model for Predicting Breast Cancer


We’re looking for an accurate, efficient and scalable means of understanding a women’s breast cancer risk. Mammography-based AI risk models provide practical advantages over traditional clinical risk models because they use a single data source: the mammogram itself.

In a large study of thousands of mammograms, artificial intelligence (AI) algorithms outperformed the standard clinical risk model for predicting the five-year risk for breast cancer. The results of the study were published today, June 6, in Radiology, a journal of the Radiological Society of North America (RSNA).

A woman’s risk of breast cancer is typically calculated using clinical models such as the Breast Cancer Surveillance Consortium (BCSC) risk model, which uses self-reported and other information on the patient—including age, family history of the disease, whether she has given birth, and whether she has dense breasts—to calculate a risk score.

“Clinical risk models depend on gathering information from different sources, which isn’t always available or collected,” said lead researcher Vignesh A. Arasu, M.D., Ph.D., a research scientist and practicing radiologist at Kaiser Permanente Northern California. “Recent advances in AI deep learning provide us with the ability to extract hundreds to thousands of additional mammographic features.”

In the retrospective study, Dr. Arasu used data associated with negative (showing no visible evidence of cancer) screening 2D mammograms performed at Kaiser Permanente Northern California in 2016. Of the 324,009 women screened in 2016 who met eligibility criteria, a random sub-cohort of 13,628 women was selected for analysis. Additionally, all 4,584 patients from the eligibility pool who were diagnosed with cancer within five years of the original 2016 mammogram were also studied. All the women were followed until 2021.

“We selected from the entire year of screening mammograms performed in 2016, so our study population is representative of communities in Northern California,” Dr. Arasu said.

The researchers divided the five-year study period into three time periods: interval cancer risk, or incident cancers diagnosed between 0 and 1 years; future cancer risk, or incident cancers diagnosed from between one and five years; and all cancer risk, or incident cancers diagnosed between 0 and 5 years.

Using the 2016 screening mammograms, risk scores for breast cancer over the five-year period were generated by five AI algorithms, including two academic algorithms used by researchers and three commercially available algorithms. The risk scores were then compared to each other and to the BCSC clinical risk score.

“All five AI algorithms performed better than the BCSC risk model for predicting breast cancer risk at 0 to 5 years,” Dr. Arasu said. “This strong predictive performance over the five-year period suggests AI is identifying both missed cancers and breast tissue features that help predict future cancer development. Something in mammograms allows us to track breast cancer risk. This is the ‘black box’ of AI.”

Some of the AI algorithms excelled at predicting patients at high risk of interval cancer, which is often aggressive and may require a second reading of mammograms, supplementary screening or short-interval follow-up imaging. When evaluating women with the highest 10% risk as an example, AI predicted up to 28% of cancers compared to 21% predicted by BCSC.

Even AI algorithms trained for short time horizons (as low as 3 months) were able to predict the future risk of cancer up to five years when no cancer was clinically detected by screening mammography. When used in combination, the AI and BCSC risk models further improved cancer prediction.

“We’re looking for an accurate, efficient and scalable means of understanding a women’s breast cancer risk,” Dr. Arasu said. “Mammography-based AI risk models provide practical advantages over traditional clinical risk models because they use a single data source: the mammogram itself.”

Dr. Arasu said some institutions are already using AI to help radiologists detect cancer on mammograms. A person’s future risk score, which takes seconds for AI to generate, could be integrated into the radiology report shared with the patient and their physician.

“AI for cancer risk prediction offers us the opportunity to individualize every woman’s care, which isn’t systematically available,” he said. “It’s a tool that could help us provide personalized, precision medicine on a national level.”

###

“Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.” Collaborating with Dr. Arasu were Laurel A. Habel, Ph.D., Ninah S. Achacoso, M.S., Diana S. M. Buist, Ph.D., Jason B. Cord, M.D., Laura J. Esserman, M.D., Nola. M. Hylton, Ph.D., M. Maria Glymour, Sc.D., John Kornak, Ph.D., Lawrence H. Kushi, Sc.D., Don A. Lewis, M.S., Vincent X. Liu, M.D., Caitlin M. Lydon, M.P.H., Diana L. Miglioretti, Ph.D., Daniel A. Navarro, M.D., Albert Pu, M.S., Li Shen, Ph.D., Weiva Sieh, M.D., Ph.D., Hyo-Chun Yoon, M.D., Ph.D., and Catherine Lee, Ph.D.

In 2023, Radiology is celebrating its 100th anniversary with 12 centennial issues, highlighting Radiology’s legacy of publishing exceptional and practical science to improve patient care.

Radiology is edited by Linda Moy, M.D., New York University, New York, N.Y., and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on breast imaging, visit RadiologyInfo.org.

MCI USA Association Solutions Welcomes Association of Pediatric Hematology/Oncology Nurses


Our partnership with MCI USA is a strategic step towards growing our community, bringing our education and training to global audiences, and optimizing outcomes for more children, adolescent, and young adult patients.

MCI USA’s Association Solutions division is pleased to welcome the Association of Pediatric Hematology/Oncology Nurses as a new full-service association management client. APHON provides leadership and expertise to pediatric hematology/oncology nurses by defining and promoting the highest standards of practice and care to the pediatric, adolescent, and young adult communities. Allison K. Summers, CAE, a global business expert and recognized association management professional, will serve as Executive Director.

“We are proud of the valuable work APHON does to provide training and community for pediatric hematology and oncology nurses,” said Janice Nuuhiwa, MSN RN NPD-BC CPHON, President, APHON. “Our partnership with MCI USA is a strategic step towards growing our community, bringing our education and training to global audiences, and optimizing outcomes for more children, adolescent, and young adult patients.”

APHON is the professional organization for pediatric hematology/oncology nurses and other pediatric hematology/oncology healthcare professionals. Its members are dedicated to promoting optimal nursing care for children, adolescents, and young adults with cancer and blood disorders, and their families. APHON’s programming includes the Pediatric Chemotherapy and Biotherapy Provider Program, core foundational curricula, and patient/family education tools.

“MCI USA will provide APHON with a full range of services, including access to global resources, strategic direction, excellent customer service, and sound accounting practices,” said Carrie Hartin, President, Association Solutions, MCI USA. “Allison K. Summers, CAE, brings the expertise and passion to lead our team to position APHON for a greater level of success and impact.”

Allison K. Summers, CAE, is a global business expert and recognized association management professional with 30-plus years of experience on the international stage working with ground-breaking industry leaders across six continents. Summers has served as the Executive Director for Zonta International and the Zonta Foundation for Women, and prior to that she was the Managing Director for Society for Incentive Travel Excellence (SITE). As the host of the Disruptive CEO Nation Podcast, she has interviewed 200+ company founders, CEOs, and cutting-edge thinkers on topics ranging from advancements in tech to leading the new workforce. Summers is an international best-selling author of books such as Building Your Brand: Make Business Happen in a Global Economy and Connect to Influence.

For nearly 30 years, MCI USA’s Association Solutions division has helped advance the goals of its mission-driven nonprofit clients. With more than 150 Association Solutions employees in its Chicago and Washington, DC, offices, MCI USA provides results-oriented experience and expertise in full-service nonprofit management, strategic planning, community building, creative services, accounting practices, technology solutions, event conceptualization, and more. MCI USA’s cause and research-based client partners include RESOLVE: The National Infertility Association, Interstitial Cystitis Association, the Medical Library Association, the MSA Coalition, Pediatric & Congenital Electrophysiology Society and the RNA Society.

# # #

ABOUT MCI

MCI is a global engagement and marketing agency. We design human-centric solutions that unleash the power of people to deliver innovation and growth for our clients. Our offering includes live & virtual events, strategic & digital communications, consulting & community solutions. We help brands, companies, associations and not-for-profits solve their challenges, bringing their people together to shape their tomorrow. MCI is an independently owned company headquartered in Geneva, Switzerland, with a global presence in 60 offices across 31 countries. http://www.mci-group.com

MCI’s US headquarters is in the Washington, DC area with offices in New York, Baltimore, Dallas, and Chicago. http://www.mci-group.com/usa

Share article on social media or email:

Maxx Orthopedics Expands Leadership Team with Danny Metcalf, Vice President Strategic Initiatives


News Image

“Danny brings deep subject matter expertise and understands how to tap into the opportunities that exist within our industry”, says Farzin Khaghani, CCO of Maxx Orthopedics.

Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, welcomes Danny Metcalf as Vice President of Strategic Initiatives.

Mr. Metcalf comes to Maxx Orthopedics with over two decades of orthopedic experience. With recognized expertise in sales leadership and business development, Mr. Metcalf will be responsible for helping shape Maxx Orthopedics’ strategic direction and working closely with leadership on delivering long-term growth plans.

“Danny brings deep subject matter expertise and understands how to tap into the opportunities that exist within our industry. He has excellent relationships and is viewed as a trusted advisor and problem-solver. I am thrilled to have him on our team”, says Farzin Khaghani, CCO of Maxx Orthopedics.

Mr. Metcalf holds a BS in Business Management from Valdosta State University.

About Maxx Orthopedics

Maxx Orthopedics is the manufacturer of the Freedom Knee® System, Libertas® Total Hip System and Quick Recovery Solutions (QRS®). The company develops and markets innovative orthopedic medical devices worldwide with a focus on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Find out more at http://www.maxxortho.com.

Share article on social media or email:

Gilad&Gilad, The Health Science Company, Re-Gambles on Las Vegas*


G&G Logo – Fight For Nerve Health

“Moving back to Vegas will allow the company to allocate more resources to the marketing efforts of our signature supplements products, AgmaSet® and AgmaVet®, targeting nerve health.”

Gilad&Gilad, a health science company with a core competency in neuroscience and a focus on the development and marketing of innovative nerve health solutions, announced today that it is presently relocating its headquarters to Las Vegas, Nevada. This move is in fact the return of the company to its home base after a two-year stint in Texas spent on clinical trials. The return to Vegas signifies the re-direction of efforts towards development and marketing of its agmatine-based nutraceutical supplements.

“Moving back to Vegas will allow the company to allocate more resources to the marketing efforts of our signature supplements products, AgmaSet® and AgmaVet®, targeting nerve health,” said Gad M. Gilad, PhD, co-founder, and CEO of Gilad&Gilad. “And at the same time, it will enable us to continue our investments in developing new novel products aimed at promoting healthy functions of bodily systems other than the nervous system,” he added.

Throughout these conversions from Nevada to Texas and back, the company continues to maintain its contract manufacturing operations in California. “We prefer to continue working with our long-time manufacturer with whom we have established good rapport and trust. Another advantage of our relocation to Vegas is the proximity to South California where our CMO is located. We can, therefore, assure our customers that the highest quality they expect of our products will be absolutely maintained.” indicated Gilad.

Source: Gilad&Gilad LLC, a health science company with core competency in Neuroscience, develops, manufactures, and markets the Agmaceuticals™ line of products, first-of-their-kind nutraceuticals, containing G-Agmatine® (the best brand of agmatine).

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

————————————————————————-

Gilad&Gilad LLC is a health science company with core competency in Neuroscience. The company has developed the exclusive Agmaceuticals™ line of products based on the breakthrough discovery of the neuroprotective properties agmatine. AgmaSet® (a dietary supplement) and AgmaVet® (for animals) are first-of-their-kind nutraceutical products containing G-Agmatine® (the best brand of agmatine), superior to existing modalities for nerve health and resilient nerve functions. – For further information, visit: https://ForNerveHealth.com. – The Company seeks investments and distributors and is open to acquisition or licensing inquiries.

About the Founders of Gilad&Gilad

Dr. Gad M. Gilad and Mrs. Varda H. Gilad began their careers in the1970s as scientists at Cornell University and The Rockefeller University, respectively. Their common scientific interests led them to join forces in 1979 and begin a long-lasting legend of a wife and husband team effort aimed at unraveling molecular mechanisms which underlie the ability of the nervous system to cope with trauma and stress. They worked together at several academic centers including the National Institutes of Health, the Weizmann Institute of Science and Harvard University. They received numerous research grants and several awards and together published over 100 scientific papers and several patents. In 1994 they discovered the neuroprotective properties of G-Agmatine® (their proprietary brand of agmatine) and patented its use for enhancing the nervous system ability to cope with trauma and stress. In 2000 following years of extensive scientific research on agmatine’s molecular mechanisms of action, they founded the Company to pursue the commercial development of G-agmatine® as a nutraceutical. In 2004, they conducted the first ever human clinical trials with G-agmatine® and demonstrated its safety and effectiveness for healthy nerve functions. In 2009, the Company set up headquarters in the United States, and established a commercial production and marketing base for the exclusive Agmaceuticals™ product line. AgmaSet®, for humans, and AgmaVet®, for animals, are novel, first-of-their-kind nutraceutical supplements, superior to any other products presently on the market for healthier nerve functions.

Share article on social media or email: